Support teaching, research, and patient care.
My scholarly interests are focused on defining, studying, and improving patients' diagnostic journeys. What prolongs the journey to the correct diagnosis and how can we shorten it? With this question in mind, we are exploring crowdsourcing, informatics/AI, health data visualization, and advanced laboratory testing as ways to help tackle the toughest cases in medicine-- complex, rare, and mystery conditions.With the COVID pandemic, the puzzling and complex illness of post-acute COVID-19 syndrome (PACS) or long COVID came to light. Together with a multidisciplinary group of physicians and researchers, we launched a program here at Stanford to advance the care and understanding of PACS. Our goal is to better understand the natural history, clinical symptomatology, immunological response, risk factors, and subgroup stratification for PACS. We are also actively assessing management strategies that may be effective for heterogeneous PACS symptoms.
Paxlovid for Treatment of Long Covid
The purpose of this study is to compare whether being treated with Paxlovid (nirmatrelvir
plus ritonavir) for 15 days works better than being treated with placebo (plus ritonavir) to
reduce severe symptoms of Long Covid (the placebo does not have any active drug).
Participants will have 5 planned visits to the study clinic over 15 weeks and will take the
drug (or placebo) for the first 15 days.
This study uses the term post-acute sequelae of SARS-CoV-2 (PASC), which is another name for
Stanford is currently not accepting patients for this trial.
For more information, please contact Study Team, 650-308-6788.
View full details